Clinical teratology: Identifying teratogenic risks in humans

Clinical Genetics

Volumn 56, Issue 6, 1999, Pages 409-420

  Polifka, Janine E ^a,c   Friedman, J M ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Birth defects; Congenital anomalies; Risk assessment; Teratogen; Teratology

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAPTOPRIL; CARBAMAZEPINE; CIGARETTE SMOKE; CLOMIFENE; COCAINE; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELBAMATE; FLUCONAZOLE; GABAPENTIN; GESTAGEN; LAMOTRIGINE; LITHIUM; METHYLENE BLUE; MISOPROSTOL; OXCARBAZEPINE; PENICILLAMINE; RETINOID; SOLVENT; TERATOGENIC AGENT; THALIDOMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; WARFARIN;

CONGENITAL MALFORMATION; FEMALE; FETUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IONIZING RADIATION; PATIENT COUNSELING; PHENYLKETONURIA; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TERATOLOGY;

ABNORMALITIES, DRUG-INDUCED; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; PREGNANCY; RISK FACTORS; TERATOGENS;

EID: 0033451099     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.1999.560601.x     Document Type: Review

References (128)

1. Brent RL. The application of the principles of toxicology and teratology in evaluating the risks of new drugs for treatment of drug addiction in women of reproductive age. NIDA Res Monogr 1995: 149: 130-184.
2. Wilson JG, Brent RL, Jordan HC. Differentiation as a determinant of the reaction of rat embryos to x-irradiation. Proc Soc Exp Biol Med 1953: 82: 67-70.
3. Rutledge JC, Generoso WM. Malformations in pregastrulution developmental toxicology. In: Korach KS, ed. Reproductive and Developmental Toxicology. New York: Marcel Dekker, 1998: 73-86.
4. Friedman JM, Polifka JE. TERIS. The Teratogen Information System. Seattle, WA: University of Washington, 1999.
5. 10 System. Database © 1994 1999. Columbia Hospital for Women Medical Center, Washington DC: Reproductive Toxicology Center (RTC), 1994.
6. Brent RL, Beckman DA. Angiotensin-converting enzyme inhibitors, and embryopathic class of drugs with unique properties: Information for clinical teratology counselors. Teratology 1991: 43: 543-546.
7. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994: 50: 339-409.
8. Mastrobattista JM. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997: 21 (2): 124-134.
9. Mehta N, Modi N. ACE inhibitors in pregnancy. Lancet 1989: 2: 96-97.
10. Lavoratti G, Seracini D, Fiorini P et al. Neonatal anuria by ACE inhibitors during pregnancy. Nephron 1997: 76: 235-236.
11. Brent RL, Beckman DA. Principles of teratology. In: Evans ML, ed. Reproductive Risks and Prenatal Diagnosis. Norwalk, CT: Appleton & Lange, 1992: 43-68.
12. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997: 17 (3): 561-564.
13. Sabers A, a'Rogvi-Hansen B, Dam M et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol Scand 1998: 97: 164-170.
14. Hanson JW. Teratogen update: fetal hydantoin effects. Teratology 1986: 33: 349-353.
15. Jager-Roman E, Deichl A, Jakob S et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986: 108: 997-1004.
16. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome. Epidemiologic and experimental findings spanning three decades. 2. Human studies. Reprod Toxicol 1991: 5 (4): 301-335.
17. Waters CH, Belai Y, Gott PS et al. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994: 51: 250-253.
18. Yerby MS, Devinsky O. Epilepsy and pregnancy. Adv. Neurol. 1994: 64: 45-63.
19. Koch S, Jager-Roman E, Losche G et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr 1996: 84: 739-746.
20. Eller DP, Patterson CA, Webb GW. Maternal and fetal implications of anticonvulsive therapy during pregnancy. Obstet Gynecol Clin North Am 1997: 24 (3): 523-534.
21. Nulman I, Scolnik D, Chitayat D. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997: 68: 18-24.
22. ACOG Educational Bulletin. Seizure disorders in pregnancy. Int J Gynaecol Obstet 1997: 56: 279-286.
23. Malone FD, D'Alton ME. Drugs in pregnancy: anticonvulsants. Semin Perinatol 1997: 21 (2): 114-123.
24. Rochester JA, Kirchner JT. Epilepsy in pregnancy. Am Fam Physician 1997: 56 (6): 1631-1638.
25. Lee BE, Feinberg M. Abraham JJ, Murthy ARK. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992: 11 (12): 1062-1064.
26. Pursley TJ, Blomquist IK, Abraham J et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996: 22: 336-340.
27. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997: 72: 253-256.
28. Thiersch JB. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A.) administered by the oral route. Am J Obstet Gynecol 1952: 63: 1298-1304.
29. Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology 1978: 17: 353-357.
30. Donnenfeld AE, Pastuszak A, Noah JS et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994: 49: 79-81.
31. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997: 40 (5): 971-973.
32. Grimes DA. Medical abortion in early pregnancy: a review of the evidence. Obstet Gynecol 1997: 89: 790-796.
33. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998: 57: 51-55.
34. Del Campo M, Jones KL, Kosaki K, Bennelt FC. High dose methotrexate during pregnancy: a case report. J Investig Med 1998: 46 (1): 119a.
35. Greenberg LH, Tanaka KR. Congenital anomalies probably induced by cyclophosphamide. JAMA 1964: 188: 423-426.
36. Garrett MJ. Teratogenic effects of combination chemotherapy. Ann Intern Med 1974: 80: 667.
37. Thomas PRM, Peckham MJ. The investigation and management of Hodgkin's disease in the pregnant patient. Cancer 1976: 38: 1443-1451.
38. Scott JR. Petal growth retardation associated with maternal administration of immunosuppressive drugs. Am J Obstet Gynecol 1977: 128: 668-676.
39. Mulvihill JJ, McKeen EA, Rosner F, Zarrabi MH. Pregnancy outcome in cancer patients. Experience in a large cooperative group. Cancer 1987: 60: 1143-1154.
40. Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ERB. Teratogenic effects of first-trimester cyclophosphamide therapy. Obsetet Gynecol 1988: 72: 462-464.
41. Friedman JM, Polifka JE. The Effects of Drugs on the Fetus and Nursing Infant: A Handbook For Health Care Professionals. Baltimore, MD: The Johns Hopkins University Press, 1994.
42. Hanson JW, Human teratology. In: Rimoin DL, Connor JM, Pyeritz RE, eds. Emery and Rimoin's Principles and Practice of Medical Genetics, vol. 1, 3rd Edn. New York: Churchill Livingslone, 1996: 697-724.
43. Herbst AL, Anderson D. Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol. Semin Surg Oncol 1990: 6 (6): 343-346.
44. Schardein JL. Chemically Induced Birth Defects. New York: Marcel Dekker, 1993: 272-278.
45. Cornel MC, ten Kate LP, te Meerman GJ. Association between ovulation stimulation, in vitro fertilisation, and neural tube defects? Teratology 1990: 42: 201-203.
46. Czeizel A. Ovulation induction and neural tube defects. Lancet 1989: 2: 167.
47. Vollset SE. Ovulation induction and neural tube defects. Lancet 1990: 335: 178.
48. Shaw GM, Lammer EJ, Velie EM. Ovulation induction by clomiphene and neural tube defects. Reprod Toxicol 1995: 9 (4): 399 400.
49. Greenland S. Ackerman DL. Clomipliene citrate and neural tube defects: a pooled analysis of controlled epidemiologic studies and recommendations for future studies. Fertil Steril 1995: 64: 936-941.
50. Cragan JD. Teratogen update: methylene blue. Teratology 1999: 60: 42-48.
51. van der Pol JG, Wolf H, Boer K et al. Jejunal atresia related to the use of methylene blue in genetic amniocentesis in twins. Br J Obstet Gynaecol 1992: 99: 141-143.
52. Gonzalez CH, Marques-Dias MJ, Kim CA et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998: 351: 1624-1627.
53. Rosa FW. Teratogen update: penicillamine. Teratology 1986: 33: 127-131.
54. Ratnavel RC, Norris PG. Penicillamine-induced elastosis perlbrans serpiginosa treated successfully with isotretinoin. Dermatology 1994: 189: 81-83.
55. Moore JA. An assessment of lithium using the IEHR evaluative process for assessing human developmental and reproductive toxicily of agents. Reprod Toxicol 1995: 9 (2): 175-210.
56. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998: 59 (Suppl 2): 18-28.
57. Cohen LS, Crush L, Goldstein J. Relapse of recurrent major depression during pregnancy. In: Presented at the Paper Session of the Annual Meeting of the American Psychiatric Association, May 1722. San Diego, CA, 1997.
58. Cohen LS. Sertraline for premenstrual dysphoric disorder. JAMA 1998: 279 (5): 357-358.
59. Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. Teratology 1986: 33: 355-364.
60. Mitchell AA. Oral retinoids. What should the prescriber know about their teratogenic hazards among women of child-bearing potential? Drug Saf 1992: 7 (2): 79-85.
61. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol 1993: 7: 175-177.
62. de Die-Smulders CEM, Sturkenboom MCJM, Veraart J et al. Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy. Teratology 1995: 52: 215-219.
63. Oakley GP, Erickson JD et al. Vitamin A and birth defects. N Engl J Med 1995: 333 (21): 1414-1415.
64. Miller RK, Hendrickx AG, Mills JL, Hummler H, Wigand U-W. Periconceptional vitamin A use: how much is teratogenic? Reprod Toxicol 1998: 12 (1): 75-88.
65. Monga M. Vitamin A and its congeners. Semin Perinatol 1997: 21 (2): 135-142.
66. Lambert WE, Meyer E, De Leenheer AP et al. Pharmacokinetics of acitretin. Acta Derm Venereol 1994: Suppl. 186: 122-123.
67. Maradit H, Geiger J-M. Potential risk of birth defects after acitretin discontinuation. Dermatology 1999: 198: 3-4.
68. Lenz W, Knapp K. Thalidomide embryopathy. Arch Environ Health 1962: 5: 100-105.
69. Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet 1992: 29: 716-723.
70. Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997: 24 (3): 499-521.
71. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980: 68: 122-140.
72. Oakley CM. Clinical perspective. Anticoagulation and pregnancy. Eur Heart J 1995: 16: 1317-1319.
73. Menger H, Lin AE, Toriello HV et al. Vitamin K deficiency embryopathy: a phenocopy of the warfarin embryopathy due to a disorder of embryonic vitamin K metabolism. Am J Med Genet 1997: 72: 129-134.
74. Sokol RJ, Clarren SK, Guidelines for use of terminology describing the impact of prenatal alcohol on the offspring. Alcohol Clin Exp Res 1989: 13 (4): 597-598.
75. Larroque B, Kaminski M. Prenatal alcohol exposure and development at preschool age: main results of a French study. Alcohol Clin Exp Res 1998: 22 (2): 295-303.
76. Gladstone J, Nulman I, Koren G. Reproductive risks of binge drinking during pregnancy. Reprod Toxicol 1996: 10 (1): 3-13.
77. Lester BM, LaGasse L, Freier K, Brunner S. Studies of cocaine exposed human infants. NIDA Res Monogr Ser 1996: 164: 175-210.
78. Landry SH, Whitney JA. The impact of prenatal cocaine exposure: studies of the developing infant. Semin Perinatol 1996: 20 (2): 99-106.
79. Chiriboga CA. Neurological correlates of fetal cocaine exposure. Ann NY Acad Sci 1998: 846: 109-125.
80. Hogan DM. Annotation: the psychological development and welfare of children of opiate and cocaine users: review and research needs. J Child Psychol Psychiatry 1998: 39 (5): 609-620.
81. Weder MM. Teratogen update: smoking and reproductive outcomes. Teratology 1997: 55: 382-388.
82. Pearson MA, Hoyme HE, Sea ver LH, Rimsza ME. Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome. Pediatrics 1994: 93: 211-215.
83. Myers GJ, Davidson PW. Prenatal methylmercury exposure and children: neurologic, developmental, and behavioral research. Environ Health Perspect 1998: 106 (Suppl. 3): 841-847.
84. Chao W-Y, Hsu C-C, Guo YL. Middle-ear disease in children exposed prenatally to polychlorinated biphenyls and polychlorinated dibenzofurans. Arch Environ Health 1997: 52 (4): 257-262.
85. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992: 90: 862-866.
86. Demmler GJ. Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis 1996: 11: 135-162.
87. Whitley RJ. Arvin AA. Herpes simplex virus infections. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th Ed. Philadelphia: WB Saunders Co. 1995: 354-376.
88. Mueller BU. Pizzo PA. Acquired immunodeficiency syndrome in the infant. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th Ed. Philadelphia: VVB Saunders Co. 1995: 377-403.
89. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998: 105: 836-848.
90. Barton LL, Seaver LH, Cassidy SB. Lymphocytic choriomeningitis virus (LCMV): a human teratogen. Reprod Toxicol 1993: 7 (6): 636.
91. Arvin AM, Maldonado YA. Other viral infections of the fetus and newborn. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th Ed. Philadelphia: WB Saunders Co, 1995: 745-756.
92. Jordan EK, Sever JL. Fetal damage caused by parvovirus infections. Reprod Toxicol 1994: 8 (2): 161-189.
93. Cooper LZ, Preblud SR, Alford CA. Rubella. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th Ed. Philadelphia: W.B. Saunders Co, 1995: 268-311.
94. Remington JS, McLeod R, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th Ed. Philadelphia: WB Saunders Co, 1995: 140-267.
95. Hira SK, Bhat GJ, Patel JB, Din SN, Attili RV, Patel MI, Baskarnathan S, Hira RS, Andu NN. Early congenital syphilis: clinico-radiologic features in 202 patients. Sex Transm Dis 1985: 12(4): 177-183.
96. Ray JG. Lues-lues: maternal and fetal considerations of syphilis. Obstet Gynecol Surv 1995: 50: 845-850.
97. Gershon AA. Chickenpox, measles and mumps. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th Ed. Philadelphia: WB Saunders Co, 1995: 565-618.
98. Lee AT, Reis D, Eriksson UJ. Hyperglycemia-induced embryonic dysmorphogenesis correlates with genomic DNA mutation frequency in vitru and in vivo. Diabetes 1999: 48 (2): 371-376.
99. Garner P. Type I diabetes mellitus and pregnancy. Lancet 1995: 346: 157-161.
100. Friedman JM. Practical teratology. In: Jauniaux E, Barnea ER, Edwards RG, eds. Embryonic Medicine and Therapy. Oxford: Oxford University Press, 1997: 481-505.
101. Wiznitzer A, Reece EA. Assessment and management of pregnancy complicated by pregestational diabetes mellitus. Pediatr Ann 1999: 28 (9): 605-613.
102. Shaw P. St. James E, Shapiro S, Waisbren E. The resource mothers program for maternal phenylketonuria. Am J Public Health 1999: 89 (5): 762-764.
103. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre-and postconception environmental radiation exposures. Teratology 1999: 59: 182-204.
104. Shepard TH. Onset of function in the human fetal thyroid: biochemical and radioautographic studies from organ culture. J Clin Endocrinol Metab 1967: 27: 945-958.
105. Berg GEB, Nystrom EH, Jacobsson L et al. Radioiodine treatment of hyperthyroidism in a pregnant woman. J Nucl Med 1998: 39 (2): 357-361.
106. Adelstein SJ. Administered radionuclides in pregnancy. Teratology 1999: 59: 236-239.
107. Anonymous. Chorionic villus sampling and amniocentesis: recommendations for prenatal counseling. MMWR Morb Mortal Wkly Rep July 21 1995: 44: 1-12.
108. Canadian Early and Mid-Trimester Amniocentesis Trial (CEMAT) Group. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998: 351: 242-247.
109. Froster UG, Jackson L. Limb defects and chorionic villus sampling: results from an international registry, 1992-94. Lancet 1996: 347: 489-494.
110. Mennuti M. A 35-year-old pregnant woman considering maternal serum screening and amniocentesis. JAMA 1996: 275 (18): 1440-1446.
111. Sundberg K, Bang J, Smidt-Jensen S, Brocks V, Lundsteen C, Parner J, Keiding N, Philip J. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 1997: 350: 697-703.
112. Jones KL. Smith's Recognizable Patterns of Human Malformations, 4th Ed. Philadelphia: W.B. Saunders Co, 1988.
113. Aase Jon M. Diagnostic Dysmorphology. New York: Plenum Medical Book Co, 1990.
114. Graham JM Jr, Jones KL, Brent RL. Contribution of clinical teratologists and geneticists to the evaluation of the etiology of congenital malformations alleged to be caused by environmental agents: ionizing radiation, electromagnetic fields, microwaves, radionuclides, and ultrasound. Teratology 1999: 59: 307-313.
115. Brent RL. Drugs and pregnancy: are the insert warnings too dire? Contemp Obstet Gynecol 1982: 20: 42-49.
116. Cordero JF, Oakley GP. Drug exposure during pregnancy: some epidemiologic considerations. Clin Obstet Gynecol 1983: 26: 418-428.
117. Shepard TH. Human teratogens: how can we sort them out? Ann NY Acad Sci 1986: 477: 105-115.
118. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998: 338: 1128 1137.
119. Koren G, Bologa M, Long D et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989: 160: 1190-1194.
120. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 1997: 37: 269-296.
121. Preston RJ. Interindividual variations in susceptibility and sensitivity: linking risk assessment and risk management. Toxicology 1996: 111 (1 - 3): 331-341.
122. Finnell RH. Teratology: general considerations and principles. J Allergy Clin Immunol 1999: 103: S337-S342.
123. Schluter WW, Reef SE, Redd SC, Dykewicz CA. Changing epidemiology of congenital rubella syndrome in the United States. J Infect Dis 1998: 178: 636-641.
124. Friedman JM. Report of the Teratology Society public affairs committee symposium on FDA classification of drugs. Teratology 1993: 48: 5-6.
125. Scialli AR. A Clinical Guide to Reproductive and Developmental Toxicology. Boca Raton: CRC Press, 1992.
126. Czeizel A, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Eng J Med 1992: 327: 1832-1835.
127. Czeizel AE. Nutritional supplementation and prevention of congenital abnormalities. Curr Opin Obstet Gynecol 1995: 7: 88-94.
128. Butterworth CE Jr, Bendich A. Folic acid and the prevention of birth defects. Ann Rev Nutr 1996: 16: 73-97.